Signalife, Inc. Recorder Transmits Heart Rate Data From Champ Car Driver in Real- Time

GREENVILLE, S.C., July 6 /PRNewswire-FirstCall/ -- Signalife, Inc. has announced that it has successfully developed and tested a novel ECG recorder capable of real-time transmission of Champ Car driver heart rate data from the vehicle to the team’s computers. The system was first tested June 22-24, 2007, during the Grand Prix of Cleveland and will be tested again during the Grand Prix of Toronto to be held July 6-8, 2007 in Toronto, Canada.

In addition to real-time heart rate transmission, the Signalife device is capable of broadcasting single ECG channel data via vehicle telemetry system. Simultaneously with transmission, the novel ECG recorder can store three full clinical-bandwidth ECG channels in the internal recorder memory for later review by the physicians.

Continuous ECG recording with live transmission capability has never been previously done on open-cockpit race car drivers. As a leader in motorsport safety, the Champ Car World Series (www.champcar.ws) and its Medical Director Dr. Chris Pinderski along with Cleveland Clinic physician Dr. Jennifer Cummings wanted to monitor driver ECGs for possible heart rhythm abnormalities in high G-force impacts which may alter on-site treatment by safety and medical personnel. Dr. Pinderski stated: “We are always looking at ways to make racing safer for our drivers. This technology allows us to monitor our drivers more closely and helps us to improve our onsite treatment. Signalife has been a great partner throughout this process and we are very happy to continue to work with them.”

The acquisition of electrocardiographic (ECG) data in the harsh environment of an open cockpit race car presents several challenges. To address these challenges, Signalife developed a novel ECG recorder capable of acquiring full clinical-bandwidth data from drivers participating in the Champ Car racing. “The data that we have been able to collect during development of this monitor is of high quality, especially considering harsh environment in which it is recorded,” stated Dr. Cummings. “The monitor performed well at our first live heart rate telemetry test and I am excited to see how it develops even further this season.” In addition to safety, the Champ Car drivers benefit from the recorded ECG data as they can better tailor physical training and improve their fitness level for the race.

Dr. Budimir Drakulic, Signalife CTO, stated: “We are grateful to Dr. Cummings from Cleveland Clinic for introducing us to this challenging problem. Dr. Pinderski and Dr. Cummings provided us with continuous medical guidelines during the device development. We are extremely satisfied with the performance of our technology in this challenging environment. Monitoring driver’s ECG during a race from medical trailer is now a reality.”

About Signalife

Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.

Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.

Signalife, Inc.

CONTACT: Kevin Kading, Signalife, Inc., +1-212-918-4606